<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Budesonide and formoterol: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Budesonide and formoterol: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Budesonide and formoterol: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="8524" href="/d/html/8524.html" rel="external">see "Budesonide and formoterol: Drug information"</a> and <a class="drug drug_patient" data-topicid="11589" href="/d/html/11589.html" rel="external">see "Budesonide and formoterol: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F3071871"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Breyna;</li>
<li>Symbicort</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52911940"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Symbicort 100 Turbuhaler;</li>
<li>Symbicort 200 Turbuhaler;</li>
<li>Symbicort Forte Turbuhaler</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1002066"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Adrenal Corticosteroid</span>;</li>
<li>
<span class="list-set-name">Adrenergic Agonist Agent</span>;</li>
<li>
<span class="list-set-name">Anti-inflammatory Agent</span>;</li>
<li>
<span class="list-set-name">Antiasthmatic</span>;</li>
<li>
<span class="list-set-name">Beta<sub>2</sub>-Adrenergic Agonist</span>;</li>
<li>
<span class="list-set-name">Bronchodilator</span>;</li>
<li>
<span class="list-set-name">Corticosteroid, Inhalant (Oral)</span>;</li>
<li>
<span class="list-set-name">Glucocorticoid</span></li></ul></div>
<div class="block dop drugH1Div" id="F142779"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2c609178-9fe2-4a01-a7ee-8e55b9565836">Asthma, maintenance treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Asthma, maintenance treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Breyna, Symbicort: </i>Metered-dose inhaler: <b>Note:</b> Do not administer more than 2 inhalations twice daily for maintenance treatment. The maximum maintenance dose is based on the formoterol component; to increase the dose of the inhaled glucocorticoid component, a separate inhaler with a higher budesonide dose per inhalation must be prescribed. If asthma symptoms occur in the period between doses, consider an inhaled, short-acting beta-2 agonist for immediate relief.</p>
<p style="text-indent:-2em;margin-left:6em;">Children 5 to &lt;12 years (limited data available for &lt;6 years): Budesonide 80 mcg/formoterol 4.5 mcg: Oral inhalation: 2 inhalations twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-NAEPP.2015']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-NAEPP.2015'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥12 years and Adolescents: <b>Note:</b> Initial dose prescribed should be based upon asthma severity and risk of exacerbation:</p>
<p style="text-indent:-2em;margin-left:8em;">Budesonide 80 mcg/formoterol 4.5 mcg: 2 inhalations twice daily. If adequate response is not seen after 1 to 2 weeks, consider the higher dose combination.</p>
<p style="text-indent:-2em;margin-left:8em;">Budesonide 160 mcg/formoterol 4.5 mcg: 2 inhalations twice daily.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Symbicort 100 Turbuhaler, Symbicort 200 Turbuhaler</i> [Canadian products]: Children ≥12 years and Adolescents: Dry powder inhaler: Oral inhalation:</p>
<p style="text-indent:-2em;margin-left:6em;">Maintenance therapy:</p>
<p style="text-indent:-2em;margin-left:8em;">Initial: 1 to 2 inhalations twice daily until symptom control, then titrate to lowest effective dosage to maintain control.</p>
<p style="text-indent:-2em;margin-left:8em;">Maintenance: 1 to 2 inhalations once or twice daily; may increase to 4 inhalations twice daily as temporary treatment in periods of worsening asthma; maximum daily dose: 8 inhalations/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:6em;">Symbicort Maintenance and Reliever Therapy (Symbicort SMART) [Canadian product]:</p>
<p style="text-indent:-2em;margin-left:8em;">Maintenance: 1 to 2 inhalations twice daily or 2 inhalations once daily.</p>
<p style="text-indent:-2em;margin-left:8em;">Reliever therapy: 1 additional inhalation as needed, may repeat if no relief for up to 6 inhalations total; maximum daily dose: 8 inhalations/<b>day</b>.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="85b2fb27-1a4a-40d6-b8b5-ab95601995d8">Asthma, acute exacerbation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Asthma, acute exacerbation:</b>
<b>Note:</b> Based on asthma severity, this regimen is for use when patient is on budesonide/formoterol as maintenance to allow for a single inhaler for both maintenance PLUS reliever; the benefit seems to be greatest with very early signs of exacerbation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-GINA.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-GINA.2018'])">Ref</a></span>). GINA guideline and study dosing is based on the dry powder inhaler product (Turbuhaler); dry powder inhaler not available in US. Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">Children 4 to 11 years: Budesonide 80 mcg/formoterol 4.5 mcg: Dry powder inhaler: Oral inhalation:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Maintenance</i>: 1 inhalation once daily at bedtime (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17166990','lexi-content-ref-15502112']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17166990','lexi-content-ref-15502112'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Reliever therapy: </i>1 inhalation as needed; may repeat if no relief; maximum daily dose: 8 inhalations/<b>day </b>(including maintenance dose) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17166990','lexi-content-ref-15502112']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17166990','lexi-content-ref-15502112'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents: Budesonide 80 mcg/formoterol 4.5 mcg: Dry powder inhaler: Oral inhalation:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Maintenance</i>: 1 inhalation twice daily <b>or </b>2 inhalations once daily at bedtime (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15502112','lexi-content-ref-16478838']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15502112','lexi-content-ref-16478838'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Reliever therapy:</i> 1 inhalation as needed; may repeat if no relief; maximum daily dose: 11 inhalations/<b>day </b>(including maintenance dose) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29768149','lexi-content-ref-16478838']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29768149','lexi-content-ref-16478838'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51083886"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block dohp drugH1Div" id="F51083887"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); use with caution and monitor closely; may lead to accumulation of budesonide and formoterol.</p></div>
<div class="block doa drugH1Div" id="F142772"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="8524" href="/d/html/8524.html" rel="external">see "Budesonide and formoterol: Drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> The maximum dose is based on the formoterol component; to increase the dose of the inhaled glucocorticoid component, a separate inhaler with a higher budesonide dose per inhalation must be prescribed.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4c809d59-12de-4789-a830-b048cd9fbce6">Asthma</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Asthma:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Asthma, intermittent symptom relief or acute exacerbations (mild to moderate):</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>Based on asthma severity, this regimen can be used as a reliever only <b>or</b> as part of a maintenance/controller <b>PLUS</b> reliever regimen (MART therapy). Patients with worsening symptoms despite initial care should seek immediate medical attention. A valved holding chamber (spacer) is recommended for use with a metered-dose inhaler (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-GINA.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-GINA.2021'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Metered-dose inhaler (off-label use):</i></p>
<p style="text-indent:-2em;margin-left:10em;">Budesonide 80 mcg/formoterol 4.5 mcg <b>or</b> budesonide 160 mcg/formoterol 4.5 mcg: <b>Oral Inhalation: </b>1 to 2 inhalations every 4 hours as needed. For persistent symptoms, may administer up to 2 inhalations every 20 minutes for 3 doses; the need for more frequent dosing suggests an incomplete response and may require further medical attention (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29768147','lexi-content-ref-31112386','lexi-content-ref-Cahill.1','lexi-content-ref-GINA.2021','lexi-content-ref-Lange-Vaidya.1','lexi-content-ref-29768149','lexi-content-ref-24321802','lexi-content-ref-16478838']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29768147','lexi-content-ref-31112386','lexi-content-ref-Cahill.1','lexi-content-ref-GINA.2021','lexi-content-ref-Lange-Vaidya.1','lexi-content-ref-29768149','lexi-content-ref-24321802','lexi-content-ref-16478838'])">Ref</a></span>). Maximum dose: 12 inhalations/day (including maintenance therapy) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-GINA.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-GINA.2021'])">Ref</a></span>); some experts limit to no more than 6 inhalations per hour for management of home exacerbations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Lange-Vaidya.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Lange-Vaidya.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Dry powder inhaler [Canadian products]:</i></p>
<p style="text-indent:-2em;margin-left:10em;">Mild persistent asthma, inhaler used as reliever therapy only: Symbicort 200 Turbuhaler (budesonide 200 mcg/formoterol 6 mcg): <b>Oral inhalation: </b>Initial: 1 to 2 inhalations, as needed, every 4 hours. For persistent symptoms, may administer up to 2 inhalations every 20 minutes for 3 doses; the need for more frequent dosing suggests an incomplete response and may require further medical attention. Maximum dose (based on delivered dose): 12 inhalations/day (including maintenance therapy) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Cahill.1','lexi-content-ref-GINA.2021','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Cahill.1','lexi-content-ref-GINA.2021','lexi-content-ref-manu.1'])">Ref</a></span>); some experts limit to no more than 6 inhalations per hour for management of home exacerbations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Lange-Vaidya.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Lange-Vaidya.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">Moderate to severe asthma, reliever therapy (as part of a combined maintenance/reliever protocol using the same inhaler): Symbicort 100 Turbuhaler or Symbicort 200 Turbuhaler (budesonide 100 mcg/formoterol 6 mcg or 200 mcg/formoterol 6 mcg): <b>Oral inhalation:</b> Initial: 1 to 2 inhalations as needed every 4 hours. For persistent symptoms, may administer up to 2 inhalations every 20 minutes for 3 doses; the need for more frequent dosing suggests an incomplete response and may require further medical attention. Maximum dose (based on delivered dose): 12 inhalations/day (including maintenance therapy) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Cahill.1','lexi-content-ref-GINA.2021','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Cahill.1','lexi-content-ref-GINA.2021','lexi-content-ref-manu.1'])">Ref</a></span>); some experts limit to no more than 6 inhalations per hour for management of home exacerbations (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Lange-Vaidya.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Lange-Vaidya.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Asthma, maintenance/controller: Note: </b> May be used as maintenance/controller only <b>or</b> as part of a maintenance/controller <b>PLUS</b> reliever regimen (MART therapy). A valved holding chamber (spacer) is recommended for use with a metered-dose inhaler (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-GINA.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-GINA.2021'])">Ref</a></span>). <b>Product selection:</b> Individualize daily budesonide dose based on severity of symptoms, typically as follows: low doses for mild persistent asthma; low to medium doses for moderate persistent asthma; and medium to high doses for severe persistent asthma. Select a product with a favorable dosage per actuation to improve convenience and adherence (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-GINA.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-GINA.2021'])">Ref</a></span>). <b>Safety: </b>The recommended dosage range and maximum dose for each inhaler is based on the formoterol component; do NOT adjust the number of inhalations to change the corticosteroid dose; use an alternative inhaler (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-GINA.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-GINA.2021'])">Ref</a></span>).</p>
<table border="1" frame="border" rules="all" style="margin-left:4em;">
<caption>
<b>Dosage Classification for Budesonide Preparations (</b>GINA 2023<b>)</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center"></th>
<th align="center">
<p style="text-indent:0em;">Low dose</p></th>
<th align="center">
<p style="text-indent:0em;">Medium dose</p></th>
<th align="center">
<p style="text-indent:0em;">High dose</p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;">Budesonide</p></td>
<td align="center">
<p style="text-indent:0em;">200 to 400 mcg/day</p></td>
<td align="center">
<p style="text-indent:0em;">&gt;400 to 800 mcg/day</p></td>
<td align="center">
<p style="text-indent:0em;">Use noncombination budesonide inhaler.</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:6em;">
<b>Usual dosage ranges, mild to moderate: </b></p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Metered-dose inhaler:</i></p>
<p style="text-indent:-2em;margin-left:10em;">Budesonide 80 mcg/formoterol 4.5 mcg: <b>Oral inhalation: </b>2 inhalations twice daily; maximum dose: 12 inhalations/day (including reliever therapy) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Fanta.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Fanta.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">Budesonide 160 mcg/formoterol 4.5 mcg: <b>Oral inhalation:</b> 2 inhalations twice daily; maximum dose: 12 inhalations/day (including reliever therapy) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Fanta.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Fanta.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Dry powder inhaler (Canadian products):</i></p>
<p style="text-indent:-2em;margin-left:10em;">Symbicort 100 or 200 Turbuhaler: Budesonide 100 mcg/formoterol 6 mcg or 200 mcg/formoterol 6 mcg: <b>Oral inhalation:</b> 1 to 2 inhalations twice daily or 2 inhalations once daily; maximum dose: 12 inhalations/day (including reliever therapy).</p>
<p style="text-indent:-2em;margin-left:10em;">Symbicort Forte Turbuhaler: Budesonide 400 mcg/formoterol 12 mcg: <b>Oral inhalation:</b> 1 inhalation once or twice daily; during periods of worsening symptoms, may temporarily increase to 2 inhalations twice daily; maximum dose: 4 inhalations/day.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Titration:</b> For patients whose symptoms are not adequately controlled after 2 to 4 weeks of therapy, may increase controller therapy in a step-wise fashion. For patients whose symptoms are well controlled for 3 to 6 months on a stable regimen, may reduce controller therapy in a step-wise fashion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Fanta.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Fanta.2'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9c6f4720-28f3-4c2d-84c9-7afdfa8fd1a7">Chronic obstructive pulmonary disease, maintenance</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic</b>
<b>obstructive pulmonary disease, maintenance:</b>
<b>Note:</b> Use of long-acting beta agonist and inhaled corticosteroid is not encouraged. In patients with persistent exacerbations on dual long-acting bronchodilator therapy or elevated eosinophil count (Group E), consider triple therapy (inhaled corticosteroid, long-acting beta agonist, and long-acting muscarinic antagonist). In addition, a short-acting bronchodilator is used for intermittent symptom relief (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-GOLD.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-GOLD.2022'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Budesonide 160 mcg/formoterol 4.5 mcg (Breyna, Symbicort): Metered-dose inhaler: <b>Oral inhalation: </b>2 inhalations twice daily.</p>
<p style="text-indent:-2em;margin-left:4em;">Budesonide 160 mcg/formoterol 4.8 mcg (Symbicort Aerospheres): Metered-dose inhaler: <b>Oral inhalation:</b> 2 inhalations twice daily.</p>
<p style="text-indent:-2em;margin-left:4em;">Budesonide 200 mcg/formoterol 6 mcg (Symbicort 200 Turbuhaler [Canadian product]): Dry powder inhaler: <b>Oral inhalation: </b>2 inhalations twice daily.</p>
<p style="text-indent:-2em;margin-left:4em;">Budesonide 400 mcg/formoterol 12 mcg (Symbicort Forte Turbuhaler [Canadian product]): Dry powder inhaler: <b>Oral inhalation: </b>1 inhalation twice daily.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991170"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doha drugH1Div" id="F50988554"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); use with caution and monitor closely; may lead to accumulation of budesonide and formoterol.</p></div>
<div class="block adr drugH1Div" id="F142749"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reported incidences are for adolescents and adults unless specified otherwise. Also see individual agents.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (3% to 11%; children: ≥3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Nasopharyngitis (7% to 11%), upper respiratory tract infection (including viral upper respiratory tract infection: 4% to 11%; children: ≥3%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypertension (adults: 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distress (7%), diarrhea (adults: 2%), oral candidiasis (1% to 6%), vomiting (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Influenza (2% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Voice disorder (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Back pain (2% to 3%), muscle spasm (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (adults: 2%), nasal congestion (3%), pharyngitis (children: ≥3%), pharyngolaryngeal pain (6% to 9%), pulmonary infection (adults with COPD: 8%; including bronchitis [2% to 5%], lower respiratory tract infection [viral]), rhinitis (children: ≥3%), sinusitis (4% to 6%)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing (any age population):</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Angina pectoris, atrial arrhythmia (including atrial fibrillation), extrasystoles, hypotension, palpitations, tachycardia, ventricular arrhythmia</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypercorticoidism signs and symptoms, hyperglycemia, hypokalemia</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Bruise</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (including anaphylaxis, angioedema, type 1 hypersensitivity reaction, type IV hypersensitivity reaction)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Agitation, behavioral changes, depression, dizziness, nervousness, restlessness, sleep disturbance, tremor</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Linear skeletal growth rate below expectation, muscle cramps</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Cataract, glaucoma, increased intraocular pressure</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Oropharyngeal candidiasis, throat irritation</p></div>
<div class="block coi drugH1Div" id="F142762"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to budesonide, formoterol, or any component of the formulation; primary treatment of status asthmaticus or other acute episodes of asthma or COPD where intensive measures are required (Breyna, Symbicort).</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Hypersensitivity to inhaled lactose.</p></div>
<div class="block war drugH1Div" id="F142747"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Adrenal suppression: May cause hypercortisolism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children or in patients receiving high doses for prolonged periods. HPA axis suppression may lead to adrenal crisis. Withdrawal and discontinuation of a corticosteroid should be done slowly and carefully. Particular care is required when patients are transferred from systemic corticosteroids to inhaled products due to possible adrenal insufficiency or withdrawal from steroids, including an increase in allergic symptoms. Adult patients receiving &gt;20 mg per day of prednisone (or equivalent) may be most susceptible. Fatalities have occurred due to adrenal insufficiency in asthmatic patients during and after transfer from systemic corticosteroids to aerosol steroids; aerosol steroids do <b>not</b> provide the systemic steroid needed to treat patients having trauma, surgery, or infections. Do not use this product to transfer patients from oral corticosteroid therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Asthma-related deaths: The use of long-acting beta-2 agonists (LABAs) as monotherapy has been associated with an increased risk of severe exacerbations and asthma-related deaths (SMART 2006; Walters 2007); additional data from other clinical trials suggests risk of asthma-related hospitalization may also be increased with LABA monotherapy in pediatric and adolescent patients. However, data from large randomized, double-blind controlled trials do not show a significant increase in risk of serious asthma-related events (including hospitalizations, intubations, and death) in adults, adolescents, and pediatric patients (aged 4 to 11 years) when fixed-dose LABAs are used with inhaled corticosteroids combined in a single inhaler compared with inhaled corticosteroid monotherapy (FDA 2017).</p>
<p style="text-indent:-2em;margin-left:4em;">• Bone density: Long-term use of inhaled corticosteroids have been associated with decreases in bone mineral density. Use with caution in patients with major risk factors for decreased bone mineral count such as prolonged immobilization, family history of osteoporosis, postmenopausal status, tobacco use, advanced age, poor nutrition, or chronic use of drugs that can reduce bone mass (eg, antiseizure medications, oral corticosteroids); high doses and/or long-term use of inhaled corticosteroids have been associated with decreases in bone mineral density.</p>
<p style="text-indent:-2em;margin-left:4em;">• Bronchospasm: Rarely, paradoxical bronchospasm may occur with use of inhaled bronchodilating agents; this should be distinguished from inadequate response.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Immediate hypersensitivity reactions (urticaria, angioedema, rash, bronchospasm) have been reported.</p>
<p style="text-indent:-2em;margin-left:4em;">• Immunosuppression: Prolonged use of corticosteroids may increase the incidence of secondary infection, mask acute infection (including fungal infections), prolong or exacerbate viral infections, or limit response to vaccines. Avoid use if possible in patients with ocular herpes; tuberculosis (TB) infection (latent TB) or disease (active TB) of the respiratory tract; or untreated viral, fungal, or bacterial or parasitic systemic infections. Exposure to chickenpox or measles should be avoided; if the patient is exposed to chickenpox, prophylaxis with varicella zoster immune globulin or pooled intravenous immunoglobulin may be indicated; if chickenpox develops, treatment with antiviral agents may be considered. If exposure to measles, prophylaxis with pooled intramuscular immunoglobulin may be indicated.</p>
<p style="text-indent:-2em;margin-left:4em;">• Lower respiratory infections: Pneumonia and other lower respiratory tract infections have been reported in patients with COPD following the use of inhaled corticosteroids; monitor COPD patients closely since pneumonia symptoms may overlap symptoms of exacerbations.</p>
<p style="text-indent:-2em;margin-left:4em;">• Oral candidiasis: Local oropharyngeal <i>Candida</i> infections have been reported; if this occurs, treat appropriately while either continuing or interrupting (if necessary) budesonide/formoterol therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Serious effects/fatalities: Do not exceed recommended dose; serious adverse events, including fatalities, have been associated with excessive use of inhaled sympathomimetics.</p>
<p style="text-indent:-2em;margin-left:4em;">• Vasculitis: Rare cases of vasculitis (eosinophilic granulomatosis with polyangiitis [formerly known as Churg-Strauss]) or other systemic eosinophilic conditions can occur; often associated with decrease and/or withdrawal of oral corticosteroid therapy following initiation of inhaled corticosteroid.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Asthma: Appropriate use: For acute asthma exacerbations, budesonide/formoterol is preferred as a reliever; however, short-acting beta-2 agonists (SABAs) may be used. In patients presenting to primary care or acute care facility, SABAs are recommended for the acute management of exacerbations (GINA 2023).</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with cardiovascular disease (arrhythmia, coronary insufficiency, or hypertension); beta agonists may cause elevation in blood pressure, heart rate and result in CNS stimulation/excitation. Beta-2 agonists may also increase risk of arrhythmias and ECG changes, such as flattening of the T-wave, prolongation of the QTc interval, and ST segment depression. Use with caution following acute MI; corticosteroids have been associated with myocardial rupture.</p>
<p style="text-indent:-2em;margin-left:4em;">• COPD: Appropriate use: Do <b>not</b> use for acute episodes of COPD. Do <b>not</b> initiate in patients with significantly worsening or acutely deteriorating COPD. Data are not available to determine if LABA use increases the risk of death in patients with COPD.</p>
<p style="text-indent:-2em;margin-left:4em;">• Diabetes: Use with caution in patients with diabetes mellitus; beta-2 agonists may increase serum glucose and aggravate preexisting diabetes mellitus and ketoacidosis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment; may lead to accumulation of budesonide and formoterol; monitor closely.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypokalemia: Use with caution in patients with hypokalemia; beta-2 agonists may decrease serum potassium (transient).</p>
<p style="text-indent:-2em;margin-left:4em;">• Ocular disease: Use with caution in patients with cataracts and/or glaucoma; increased intraocular pressure, open-angle glaucoma, and cataracts have occurred with prolonged use of inhaled corticosteroids. Consider routine eye exams in chronic users.</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizure disorders: Use with caution in patients with seizure disorders; beta agonists may result in CNS stimulation/excitation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Thyroid disease: Changes in thyroid status may necessitate dosage adjustments; metabolic clearance of corticosteroids increases in hyperthyroid patients and decreases in hypothyroidism.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: LABAs when used as monotherapy, may increase the risk of asthma-related hospitalization in pediatric and adolescent patients. When LABAs are used in a fixed-dose combination with inhaled corticosteroids, data from large clinical trials in adolescents do not show a significant increase in the risk of serious asthma-related events (hospitalizations, intubations, death) compared to inhaled corticosteroids alone. Orally inhaled corticosteroids may cause a reduction in growth velocity in pediatric patients (~1 centimeter per year [range 0.3 to 1.8 cm per year] and related to dose and duration of exposure). To minimize the systemic effects of orally inhaled corticosteroids, each patient should be titrated to the lowest effective dose. Growth should be routinely monitored in pediatric patients.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Discontinuation of systemic corticosteroids: Withdraw systemic corticosteroid therapy with gradual tapering of dose; consider reducing the daily prednisone dose by 2.5 mg on a weekly basis beginning after at least 1 week of inhalation therapy. Monitor lung function, beta agonist use, asthma symptoms, and for signs and symptoms of adrenal insufficiency (fatigue, lassitude, weakness, nausea and vomiting, hypotension) during withdrawal.</p></div>
<div class="block prod-avail drugH1Div" id="F58219200"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Symbicort Aerosphere: FDA approved April 2023; anticipated availability is unknown.</p></div>
<div class="block dosfc drugH1Div" id="F46518223"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:0em;display:inline">Symbicort 6.9 g canisters contain 60 actuations, and the 10.2 g canisters contain 120 actuations.</p></div>
<div class="block foc drugH1Div" id="F142757"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Aerosol, Inhalation: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Breyna: Budesonide 80 mcg and formoterol fumarate dihydrate 4.5 mcg per actuation (10.3 g); Budesonide 160 mcg and formoterol fumarate dihydrate 4.5 mcg per actuation (10.3 g)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Symbicort: Budesonide 80 mcg and formoterol fumarate dihydrate 4.5 mcg per actuation (6.9 g, 10.2 g); Budesonide 160 mcg and formoterol fumarate dihydrate 4.5 mcg per actuation (6 g, 10.2 g)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: Budesonide 160 mcg and formoterol fumarate dihydrate 4.5 mcg per actuation (10.2 g); Budesonide 80 mcg and formoterol fumarate dihydrate 4.5 mcg per actuation (10.2 g)</p></div>
<div class="block geq drugH1Div" id="F53482923"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F5551127"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Aerosol</b> (Breyna Inhalation)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">80-4.5 mcg/ACT (per gram): $37.81</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">160-4.5 mcg/ACT (per gram): $43.22</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Aerosol</b> (Budesonide-Formoterol Fumarate Inhalation)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">80-4.5 mcg/ACT (per gram): $34.56</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">160-4.5 mcg/ACT (per gram): $39.51</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Aerosol</b> (Symbicort Inhalation)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">80-4.5 mcg/ACT (per gram): $24.07</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">160-4.5 mcg/ACT (per gram): $31.84</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52911941"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Aerosol Powder Breath Activated, Inhalation: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Symbicort 100 Turbuhaler: Budesonide 100 mcg and formoterol fumarate 6 mcg per inhalation (1 ea) [contains lactose]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Symbicort 200 Turbuhaler: Budesonide 200 mcg and formoterol fumarate 6 mcg per inhalation (1 ea) [contains lactose]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Symbicort Forte Turbuhaler: Budesonide 400 mcg and formoterol fumarate 12 mcg per inhalation (1 ea) [contains lactose]</p></div>
<div class="block admp drugH1Div" id="F52612326"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral inhalation: Rinse mouth with water after use and spit to reduce risk of oral candidiasis.</p>
<p style="text-indent:-2em;margin-left:4em;">Metered-dose inhaler: Prior to first use, inhaler must be primed by releasing 2 test sprays into the air (away from the face); shake well for 5 seconds before each spray. Inhaler must be reprimed if inhaler has not been used for &gt;7 days or has been dropped. Shake well for 5 seconds before each use. Discard after labeled number of inhalations has been used or within 3 months after foil wrap has been removed; do not use immerse in water or use "float test" to determine number of inhalations left.</p>
<p style="text-indent:-2em;margin-left:4em;">Dry powder inhaler: Symbicort Turbuhaler [Canadian product]: To prepare inhaler prior to use, remove cover and hold the inhaler in upright position and turn the red grip as far as it will go in one direction and then turn it as far as it will go in the other direction. Prior to first use, this procedure should be done twice; with subsequent dosing, perform this procedure once even when not used regularly. Clicking sound means inhaler is loaded with dose and ready for use. Place mouthpiece between teeth and close lips over mouthpiece. Inhale deeply and forcefully. Do not exhale through inhaler. If the Turbuhaler is dropped, shaken, or breathed into after it is loaded, the dose will be lost and a new dose will need to be loaded. When the "0" on the red background has reached the middle of the window, the inhaler should be discarded. Do not wash inhaler with water; clean mouthpiece using a dry wipe every 7 days.</p></div>
<div class="block adm drugH1Div" id="F142759"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Metered-dose inhaler:</p>
<p style="text-indent:-2em;margin-left:4em;">Symbicort Aerospheres: For oral inhalation only, administered every morning and evening, approximately 12 hours apart. Prior to first use, inhaler must be primed by releasing 4 tests sprays into the air; shake well before each spray. Inhaler must be reprimed with 2 sprays if not used for &gt;7 days, it has been dropped, or after weekly cleaning. Shake well before each use. Discard inhaler after the labeled number of inhalations have been used or within 3 months after removal from foil pouch. Rinse mouth with water (spit out without swallowing) after each use. Clean inhaler once weekly; remove canister from actuator; do not clean or allow canister to get wet. With the cap removed hold the actuator under warm tap water for ~30 seconds; turn actuator upside down and run warm tap water through for about another 30 seconds. Shake actuator well and ensure medicine build-up has been completely washed away; repeat rinsing with water if medicine build-up still remains. Allow actuator to dry (eg, overnight); do not put canister into a wet actuator.</p>
<p style="text-indent:-2em;margin-left:4em;">Breyna, Symbicort: For oral inhalation only administered every morning and evening, approximately 12 hours apart. Prior to first use, inhaler must be primed by releasing 2 test sprays into the air; shake well for 5 seconds before each spray. Inhaler must be reprimed if not used for &gt;7 days or if it has been dropped. Shake well for 5 seconds before each use. Discard inhaler after the labeled number of inhalations have been used or within 3 months after removal from foil pouch. Rinse mouth with water (spit out without swallowing) after each use. Do not wash inhaler with water; clean mouthpiece using a dry wipe every 7 days.</p>
<p style="text-indent:-2em;margin-left:4em;">Delivery of dose: Instruct patient to place mouthpiece gently between teeth, closing lips around inhaler. Instruct patient to inhale deeply, press the top counter, and hold breath for up to 10 seconds or as long as they comfortably can. Remove mouthpiece from mouth prior to exhalation. Patient should not breathe out through the mouthpiece. Wait ≥30 seconds prior to the second inhalation dose.</p>
<p style="text-indent:-2em;margin-left:2em;">Dry powder inhaler: Symbicort Turbuhaler [Canadian product]:</p>
<p style="text-indent:-2em;margin-left:4em;">To “load” inhaler: Turn red grip on inhaler as far as it will move in one direction, then turn in opposite direction as far as it will go (inhaler is “loaded” with a dose, indicated by a “click”). Prior to first use, this procedure should be done twice, it does not need to be repeated with subsequent uses even when not used regularly.</p>
<p style="text-indent:-2em;margin-left:4em;">Delivery of dose: Instruct patient to place mouthpiece gently between teeth, closing lips around inhaler. Instruct patient to inhale deeply and hold breath for as long as they comfortably can. Remove mouthpiece prior to exhalation. Patient should not breathe out through the mouthpiece. Dose is lost if patient drops, shakes, or exhales into inhaler after a dose has been loaded. After use of the inhaler, patient should rinse mouth/oropharynx with water and spit out rinse solution. Do not wash inhaler with water; clean mouthpiece using a dry wipe every 7 days.</p></div>
<div class="block sts drugH1Div" id="F142767"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Breyna 80/4.5, Breyna 160/4.5, Symbicort 80/4.5, Symbicort 160/4.5: Store at 20°C to 25°C (68°F to 77°F) with mouthpiece down; temperatures above 49°C (120°F) may cause bursting. Contents under pressure; do not puncture, incinerate, or store near heat or open flame. Discard inhaler after the labeled number of inhalations have been used (the dose counter will read “0”) or within 3 months after removal from foil pouch.</p>
<p style="text-indent:-2em;margin-left:2em;">Symbicort Aerosphere 160/4.8: Store at 20°C to 25°C (68°F to 77°F); excursion permitted to 15°C to 30°C (59°F to 77°F). Temperatures above 49°C (120°F) may cause bursting. Protect from heat and light. Contents under pressure; do not puncture, incinerate, or store near heat or open flame. Discard inhaler after the labeled number of inhalations have been used (the dose counter will read “0”) or within 3 months after removal from foil pouch.</p>
<p style="text-indent:-2em;margin-left:2em;">Symbicort Turbuhaler [Canadian product]: Store at room temperature of 15°C to 30°C (59°F to 77°F).</p></div>
<div class="block usep drugH1Div" id="F53565724"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Maintenance treatment of asthma (All strengths: FDA approved in ages ≥6 years and adults); maintenance treatment of airflow obstruction associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema (160/4.5 strength only: FDA approved in adults); <b>NOT</b> indicated for the relief of acute bronchospasm.</p></div>
<div class="block cyt drugH1Div" id="F142780"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">Refer to individual components.</p></div>
<div class="block dri drugH1Div" id="F142751"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Atomoxetine: May enhance the tachycardic effect of Beta2-Agonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atomoxetine: May enhance the hypertensive effect of Sympathomimetics. Atomoxetine may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atosiban: Beta2-Agonists may enhance the adverse/toxic effect of Atosiban. Specifically, there may be an increased risk for pulmonary edema and/or dyspnea. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta2-Agonists (Long-Acting): May enhance the adverse/toxic effect of other Beta2-Agonists (Long-Acting).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta-Blockers (Beta1 Selective): May diminish the bronchodilatory effect of Beta2-Agonists. Of particular concern with nonselective beta-blockers or higher doses of the beta1 selective beta-blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta-Blockers (Nonselective): May diminish the bronchodilatory effect of Beta2-Agonists.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Caffeine and Caffeine Containing Products: May enhance the adverse/toxic effect of Formoterol. Caffeine and Caffeine Containing Products may enhance the hypokalemic effect of Formoterol.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cannabinoid-Containing Products: May enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cocaine (Topical): May enhance the hypertensive effect of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart rate and for any evidence of myocardial ischemia with concurrent use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cosyntropin: Corticosteroids (Orally Inhaled) may diminish the diagnostic effect of Cosyntropin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Budesonide (Oral Inhalation).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Budesonide (Oral Inhalation). Management: Consider alternatives to this combination when possible. If combined, monitor for increased corticosteroid adverse effects during coadministration of inhaled budesonide and strong CYP3A4 inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Desmopressin: Corticosteroids (Orally Inhaled) may enhance the hyponatremic effect of Desmopressin. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxofylline: Sympathomimetics may enhance the adverse/toxic effect of Doxofylline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Guanethidine: May enhance the arrhythmogenic effect of Sympathomimetics. Guanethidine may enhance the hypertensive effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: QT-prolonging Agents (Indeterminate Risk - Caution) may enhance the QTc-prolonging effect of Haloperidol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kratom: May enhance the adverse/toxic effect of Sympathomimetics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levothyroxine: May enhance the adverse/toxic effect of Sympathomimetics. Specifically, the risk of coronary insufficiency may be increased in patients with coronary artery disease. Levothyroxine may enhance the therapeutic effect of Sympathomimetics. Sympathomimetics may enhance the therapeutic effect of Levothyroxine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Consider initial dose reductions of sympathomimetic agents, and closely monitor for enhanced blood pressure elevations, in patients receiving linezolid.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loop Diuretics: Beta2-Agonists may enhance the hypokalemic effect of Loop Diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loxapine: Agents to Treat Airway Disease may enhance the adverse/toxic effect of Loxapine. More specifically, the use of Agents to Treat Airway Disease is likely a marker of patients who are likely at a greater risk for experiencing significant bronchospasm from use of inhaled loxapine.  Management: This is specific to the Adasuve brand of loxapine, which is an inhaled formulation.  This does not apply to non-inhaled formulations of loxapine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methacholine: Beta2-Agonists (Long-Acting) may diminish the therapeutic effect of Methacholine.  Management: Hold long-acting beta<sub>2</sub> agonists for 36 hours before methacholine use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors: May enhance the adverse/toxic effect of Beta2-Agonists.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nirmatrelvir and Ritonavir: May increase the serum concentration of Budesonide (Oral Inhalation).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ozanimod: May enhance the hypertensive effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Agents (Highest Risk): QT-prolonging Agents (Indeterminate Risk - Caution) may enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Solriamfetol: Sympathomimetics may enhance the hypertensive effect of Solriamfetol. Sympathomimetics may enhance the tachycardic effect of Solriamfetol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tedizolid: May enhance the hypertensive effect of Sympathomimetics. Tedizolid may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Theophylline Derivatives: Beta2-Agonists may enhance the adverse/toxic effect of Theophylline Derivatives. Specifically, sympathomimetic effects may be increased. Theophylline Derivatives may enhance the hypokalemic effect of Beta2-Agonists. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: Beta2-Agonists may enhance the hypokalemic effect of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tobacco (Smoked): May diminish the therapeutic effect of Corticosteroids (Orally Inhaled).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tricyclic Antidepressants: May enhance the adverse/toxic effect of Beta2-Agonists.<i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F3071872"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Adverse events were observed in animal reproduction studies using this combination. Refer to individual monographs.</p></div>
<div class="block mopp drugH1Div" id="F53565726"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Monitor growth in pediatric patients (via stadiometry). Check mucous membranes for signs of fungal infection. Monitor asthma symptoms, FEV<sub>1</sub>, peak flow, and/or other pulmonary function tests; monitor signs/symptoms of HPA axis suppression/adrenal insufficiency; ocular effects (eg, cataracts, increased intraocular pressure, glaucoma); bone mineral density. Monitor blood pressure, heart rate, CNS stimulation, serum glucose, and serum potassium. Monitor for increased use of short-acting beta<sub>2</sub>-agonist inhalers; may be marker of a deteriorating asthma condition.</p></div>
<div class="block pha drugH1Div" id="F142746"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:-2em;margin-left:2em;">Formoterol: Relaxes bronchial smooth muscle by selective action on beta<sub>2</sub> receptors with little effect on heart rate; formoterol has a long-acting effect.</p>
<p style="text-indent:-2em;margin-left:2em;">Budesonide: A corticosteroid which controls the rate of protein synthesis, depresses the migration of polymorphonuclear leukocytes/fibroblasts, and reverses capillary permeability and lysosomal stabilization at the cellular level to prevent or control inflammation.</p></div>
<div class="block phk drugH1Div" id="F142761"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;display:inline">See individual agents.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F142765"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Bufomix easyhaler | Symbicort</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Frevia | Maxivent | Neumocort plus | Symbicort | Symbicort forte | Symbicort-m</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Duoresp spiromax | Symbicort</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Biresp spiromax | Duoresp spiromax | Symbicort</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Budison F | Formatide | Formocort | Oxycort | Symbion</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Airbufo forspiro | Bufomix | Symbicort</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Airbufo forspiro | Duoresp spiromax | Symbicoct | Symbicort</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Symbicort | Symbicort turbuhaler | Vannair</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Symbicort | Vannair</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Symbicort turbuhaler</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Bendorin | Bronlival easyhaler | Duoresp spiromax | Neumocort plus | Symbicort | Vannair</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Budesonide and formoterol fumarate | Symbicort</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Budemar Duo | Busterol | Complebrez | Foracort | Prehistam | Symbicort | Symbicort rapihaler | Symbicort turbuhaler | Vannair</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Airbufo forspiro | Bufomix | Duoresp spiromax | Symbicort</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Airbufo forspiro | Budfor | Bufomix | Bufori easyhaler | Duoresp spiromax | Edoflo | Gibiter | Pulmelia | Symbicort</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Airtec fb | Etiterol Compuesto | Fortel b | Neumocort plus | Symbicort | Vannair</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Busterol | Dassara</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Airbufo forspiro | Bufomix | Symbicort</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Symbicort</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Biresp spiromax | Budesonida/formoterol cipla | Bufomix | Duoresp spiromax | Gibiter | Rilast | Symbicort</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Bufomix | Symbicort | Symbicort tu</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Duoresp spiromax | Gibiter easyhaler | Symbicort | Symbicort rapihaler</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Duoresp spiromax | Fobumix Easyhaler | Symbicort | Wockair</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Pulmoton | Symbicort</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Symbicort | Vannair</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Duoresp spiromax | Symbicort</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Bufomix | Duoresp spiromax | Pulmalio | Symbicort</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Symbicort</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Airbufo forspiro | Bufomix | Duoresp spiromax | Symbicort</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Symbicort</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Airtec fb | Budamate | Budetrol | Budetrol forte | Budevent f | Combihale Fm | Combihale-fb | Digihaler FB | Fb hale | Fomtide | Foracort | Foracort forte | Formonide | Peakhale Fb | Pulmosmart | Quikhale fb | Symbicort | Symbiva | Unipuff fb</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Airbufo forspiro | Assieme | Duoresp spiromax | Fobuler | Gibiter | Pulmelia | Sinestic | Symbicort</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Bufomix | Symbicort</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Budeforu | Budeforu jg | Symbicort | Symbicort turbuhaler</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Foracort | Foralin | Forb | Formonide | Symbicort turbuhaler</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Duoresp spiromax | Duorespi spiromax | Symbicort | Symbicort rapihaler</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Symbicort</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Foracort | Symbicort</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Bufomix | Duoresp spiromax | Symbicort</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Bufomix | Symbicort</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Airbufo forspiro | Bufomix | Duoresp spiromax | Symbicort</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Foracort | Symbicort</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Symbicort | Symbicort turbuhaler | Vannair</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Foracort | Symbicort</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Fortide | Symbicort turbuhaler</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Airbufo forspiro | Assieme | BiResp | Bufoler Easyhaler | Duoresp spiromax | Sinestic | Symbicort | Vylaer</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Bufomix easyhaler | Duoresp spiromax | Symbicort | Symbicort forte</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Duoresp spiromax | Symbicort | Vannair</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Neumocort plus | Symbicort</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Symbicort</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Foracort | Fortide | Zirva</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Bufomix | Duoresp spiromax | Symbicort</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Budesonide and Formoterol | Budesonide and formoterol fumarate dihydrate | Symbicort</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Assieme | Biresp spiromax | Bufomix | Duoresp spiromax | Gibiter | Symbicort</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Neumocort plus</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Bufomix Easyhaler | Respicort | Symbicort | Symbicort Turbuhaler</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Airbufo forspiro | Duoresp spiromax | Symbicort</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Duoresp spiromax | Simbicort turbuhaler | Symbicort | Symbicort rapihaler</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Bufomix easyhaler | Symbicort</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Bufomide Easyhaler | Bufomix | Bufori easyhaler | Duoresp spiromax | Gardette | Symbicort | Symbicort forte turbuhaler | Symbicort turbuhaler</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Duoresp spiromax | Symbicort</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Duoresp spiromax | Symbicort</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Bufomix easyhaler | Symbicort</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Symbicort</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Symbicort</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Combipack Easyhaler | Forpack | Respiday | Symbicort</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Symbicort | Symbicort rapihaler</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Bufomix | Symbicort</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Foracort | Formonide | Symbicort</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Maxivent | Neumocort plus | Symbicort | Symbicort-m | Vannair</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Complebrez | Foracort | Rolastym | Symbicort | Vannair</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Symbicord | Vannair</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Symbicort</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-29768147">
<a name="29768147"></a>Bateman ED, Reddel HK, O'Byrne PM, et al. As-needed budesonide-formoterol versus maintenance budesonide in mild asthma. <i>N Engl J Med</i>. 2018;378(20):1877-1887. doi:10.1056/NEJMoa1715275<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/budesonide-and-formoterol-pediatric-drug-information/abstract-text/29768147/pubmed" id="29768147" target="_blank">29768147</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31112386">
<a name="31112386"></a>Beasley R, Holliday M, Reddel HK, et al; Novel START Study Team. Controlled trial of budesonide-formoterol as needed for mild asthma. <i>N Engl J Med</i>. 2019;380(21):2020-2030. doi:10.1056/NEJMoa1901963<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/budesonide-and-formoterol-pediatric-drug-information/abstract-text/31112386/pubmed" id="31112386" target="_blank">31112386</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17166990">
<a name="17166990"></a>Bisgaard H, Le Roux P, Bjåmer D, Dymek A, Vermeulen JH, Hultquist C. Budesonide/formoterol maintenance plus reliever therapy: a new strategy in pediatric asthma. <i>Chest</i>. 2006;130(6):1733-1743.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/budesonide-and-formoterol-pediatric-drug-information/abstract-text/17166990/pubmed" id="17166990" target="_blank">17166990</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Breyna (budesonide/formoterol) [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals Inc; September 2020.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/budesonide-and-formoterol-pediatric-drug-information/abstract-text/Breyna.1/pubmed" id="Breyna.1" target="_blank">Breyna.1</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18405951">
<a name="18405951"></a>Busse WW, Pedersen S, Pauwels RA, et al. The Inhaled Steroid Treatment As Regular Therapy in Early Asthma (START) study 5-year follow-up: effectiveness of early intervention with budesonide in mild persistent asthma. <i>J Allergy Clin Immunol</i>. 2008;121(5):1167-1174. doi:10.1016/j.jaci.2008.02.029<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/budesonide-and-formoterol-pediatric-drug-information/abstract-text/18405951/pubmed" id="18405951" target="_blank">18405951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cahill.1">
<a name="Cahill.1"></a>Cahill KN. Acute exacerbations of asthma in adults: Home and office management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">https://www.uptodate.com</a>. Accessed January 25, 2024.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fanta.2">
<a name="Fanta.2"></a>Fanta CH. An overview of asthma management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">https://www.uptodate.com</a>. Accessed August 30, 2021b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fanta.1">
<a name="Fanta.1"></a>Fanta CH, Lange-Vaidya N. Treatment of intermittent and mild persistent asthma in adolescents and adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">https://www.uptodate.com</a>. Accessed August 30, 2021a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-GINA.2018">
<a name="GINA.2018"></a>Global Initiative for Asthma (GINA). GINA report, global strategy for asthma management and prevention. https://ginasthma.org/wp-content/uploads/2018/04/wms-GINA-2018-report-tracked_v1.3.pdf. Updated 2018. Accessed April 10, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-GINA.2021">
<a name="GINA.2021"></a>Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. https://ginasthma.org/2023-gina-main-report/. Updated 2023. Accessed August 23, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-GOLD.2022">
<a name="GOLD.2022"></a>Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for prevention, diagnosis and management of COPD: 2023 report. https://goldcopd.org/wp-content/uploads/2023/01/GOLD-2023-ver-1.2-7Jan2023_WMV.pdf. Updated 2023. Accessed January 30, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lange-Vaidya.1">
<a name="Lange-Vaidya.1"></a>Lange-Vaidya N, Hartert T. Initiating asthma therapy and monitoring in adolescents and adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">https://www.uptodate.com</a>. Accessed January 12, 2024.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NAEPP.2015">
<a name="NAEPP.2015"></a>National Asthma Education and Prevention Program (NAEPP). Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. NIH Publication No. 08-4051. Bethesda, MD: US Department of Health and Human Services, National Institutes of Health, National Heart, Lung, and Blood Institute; 2007. <a href="http://www.nhlbi.nih.gov/files/docs/guidelines/asthgdln.pdf" target="_blank">http://www.nhlbi.nih.gov/files/docs/guidelines/asthgdln.pdf</a>. Accessed June 22, 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16424409">
<a name="16424409"></a>Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM; SMART Study Group. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. <i>Chest</i>. 2006;129(1):15-26.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/budesonide-and-formoterol-pediatric-drug-information/abstract-text/16424409/pubmed" id="16424409" target="_blank">16424409</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15502112">
<a name="15502112"></a>O'Byrne PM, Bisgaard H, Godard PP, et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. <i>Am J Respir Crit Care Med</i>. 2005;171(2):129-136.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/budesonide-and-formoterol-pediatric-drug-information/abstract-text/15502112/pubmed" id="15502112" target="_blank">15502112</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29768149">
<a name="29768149"></a>O'Byrne PM, FitzGerald JM, Bateman ED, et al. Inhaled combined budesonide-formoterol as needed in mild asthma. <i>N Engl J Med</i>. 2018;378(20):1865-1876. doi:10.1056/NEJMoa1715274<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/budesonide-and-formoterol-pediatric-drug-information/abstract-text/29768149/pubmed" id="29768149" target="_blank">29768149</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24321802">
<a name="24321802"></a>Patel M, Pilcher J, Pritchard A, et al; SMART Study Group. Efficacy and safety of maintenance and reliever combination budesonide-formoterol inhaler in patients with asthma at risk of severe exacerbations: a randomised controlled trial. <i>Lancet Respir Med</i>. 2013;1(1):32-42. doi:10.1016/S2213-2600(13)70007-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/budesonide-and-formoterol-pediatric-drug-information/abstract-text/24321802/pubmed" id="24321802" target="_blank">24321802</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16478838">
<a name="16478838"></a>Rabe KF, Pizzichini E, Ställberg B, et al. Budesonide/formoterol in a single inhaler for maintenance and relief in mild-to-moderate asthma: a randomized, double-blind trial. <i>Chest</i>. 2006;129(2):246-256. doi:10.1378/chest.129.2.246<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/budesonide-and-formoterol-pediatric-drug-information/abstract-text/16478838/pubmed" id="16478838" target="_blank">16478838</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer’s labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Rennard.1">
<a name="Rennard.1"></a>Rennard SI, Tashkin DP, McElhattan J, et al, “Long-Term Efficacy of Budesonide/Formoterol Administered Via One Pressurized Metered-Dose Inhaler in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease [poster],” <i>Chest</i>, 2008, 134:103001S.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Rennard.2">
<a name="Rennard.2"></a>Rennard SI, Tashkin DP, McElhattan J, et al, “Long-Term Tolerability of Budesonide and Formoterol Administered in One Pressurized Metered-Dose Inhaler in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease,” <i>Chest</i>, 2008, 134:103003S.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29554195">
<a name="29554195"></a>Sobieraj DM, Weeda ER, Nguyen E, et al. Association of inhaled corticosteroids and long-acting β-agonists as controller and quick relief therapy with exacerbations and symptom control in persistent asthma: a systematic review and meta-analysis. <i>JAMA</i>. 2018;319(14):1485-1496. doi: 10.1001/jama.2018.2769.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/budesonide-and-formoterol-pediatric-drug-information/abstract-text/29554195/pubmed" id="29554195" target="_blank">29554195</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Symbicort.3">
<a name="Symbicort.3"></a>Symbicort Aerosphere (budesonide/formoterol) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; April 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Symbicort.1">
<a name="Symbicort.1"></a>Symbicort (budesonide/formoterol) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; September 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Symbicort.2">
<a name="Symbicort.2"></a>Symbicort Turbuhaler and Forte Turbuhaler (budesonide/formoterol) [product monograph]. Mississauga, Ontario, Canada: AstraZeneca Canada Inc; February 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Tashkin.2008">
<a name="Tashkin.2008"></a>Tashkin DP, Rennard SI, Martin P, et al, “Efficacy of Budesonide/Formoterol Administered Via One Pressurized Metered-Dose Inhaler Over 6 Months in Patients With Chronic Obstructive Pulmonary Disease,” <i>Chest</i>, 2008, 134:105001S.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.2007">
<a name="HHS.2007"></a>US Department of Health and Human Services; National Institutes of Health; National Heart, Lung, and Blood Institute. National Asthma Education and Prevention Program Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. Full Report 2007. <a href="http://www.nhlbi.nih.gov/files/docs/guidelines/asthgdln.pdf" target="_blank">http://www.nhlbi.nih.gov/files/docs/guidelines/asthgdln.pdf</a>. Published August 28, 2007.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.2017">
<a name="FDA.2017"></a>US Food and Drug Administration. FDA drug safety communication: FDA review finds no significant increase in risk of serious asthma outcomes with long-acting beta agonists (LABAs) used in combination with inhaled corticosteroids (ICS). <a href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-review-finds-no-significant-increase-risk-serious-asthma-outcomes" target="_blank">https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-review-finds-no-significant-increase-risk-serious-asthma-outcomes</a>. Published December 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17253458">
<a name="17253458"></a>Walters EH, Gibson PG, Lasserson TJ, Walters JA. Long-acting beta2-agonists for chronic asthma in adults and children where background therapy contains varied or no inhaled corticosteroid. <i>Cochrane Database Syst Rev</i>. 2007;(1):CD001385. Published 2007 Jan 24. doi:10.1002/14651858.CD001385.pub2.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/budesonide-and-formoterol-pediatric-drug-information/abstract-text/17253458/pubmed" id="17253458" target="_blank">17253458</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 12959 Version 270.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
